Nom du produit:4-(((Benzyloxy)carbonyl)amino)benzoic acid
IUPAC Name:4-{[(benzyloxy)carbonyl]amino}benzoic acid
- CAS:5330-71-2
- Formule moléculaire:C15H13NO4
- Pureté:95%
- Numéro de catalogue:CM322678
- Poids moléculaire:271.27
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:5330-71-2
- Formule moléculaire:C15H13NO4
- Point de fusion:-
- Code SMILES:O=C(O)C1=CC=C(NC(OCC2=CC=CC=C2)=O)C=C1
- Densité:
- Numéro de catalogue:CM322678
- Poids moléculaire:271.27
- Point d'ébullition:
- N° Mdl:MFCD00610465
- Stockage:
Column Infos
- Mitapivat
- Jan. 03 2024, Agios announces Phase 3 ENERGIZE study of PYRUKYND (Mitapivat) met primary endpoint and both key secondary endpoints in adults with non-transfusion-dependent(NTD) alpha- or beta-thalassemia. The positive data showed Mitapivat’s potential to become the first oral therapy approved for NTD thalassemia.
Mitapivat is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the US, and for the treatment of PK deficiency in adult patients in the EU. By activating and stabilizing mutant pyruvate kinase, Mitapivat targets the underlying enzymatic defect that causes chronic hemolysis and ineffective erythropoiesis in order to restore enzyme activity.